Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06148038 · ClinicalTrials.gov registry record · Phase 1
CBD for Breast Cancer Primary Tumors
A Phase 1 study, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT06148038 is a Phase 1 study that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 84 participants.
The verdict
NCT06148038, a Phase 1 study, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. Patients will be randomized 2:2:1:1 to either CBD low dose, CBD high dose, matching low dose placebo, or matching high dose placebo using permuted block randomization with random block sizes of 6 or 12. The time window between CBD or placebo initiation and surgery will be between 5 and 56 days.
Interventions
- OTHER Control
- DRUG CBD Oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2029-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06148038
The ClinicalTrials.gov registry entry for NCT06148038 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT06148038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06148038 about?
NCT06148038 is a clinical study titled "CBD for Breast Cancer Primary Tumors". This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. Patients will be randomized 2:2:1:1 to either CBD low dose, CBD high dose, matching low dose placebo, or matching high dose placebo using perm...
What is the current status of trial NCT06148038?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-09-15. Estimated completion is 2029-03-25.
What interventions are being tested in trial NCT06148038?
The interventions under investigation include: Control (OTHER), CBD Oral (DRUG).
Who is sponsoring clinical trial NCT06148038?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.